WO2000066724A3 - Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna - Google Patents
Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna Download PDFInfo
- Publication number
- WO2000066724A3 WO2000066724A3 PCT/EP2000/003708 EP0003708W WO0066724A3 WO 2000066724 A3 WO2000066724 A3 WO 2000066724A3 EP 0003708 W EP0003708 W EP 0003708W WO 0066724 A3 WO0066724 A3 WO 0066724A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human bcl
- oligonucleotide derivatives
- mrna
- directed against
- bcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44025/00A AU4402500A (en) | 1999-04-30 | 2000-04-26 | Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
EP00925239A EP1181361A2 (en) | 1999-04-30 | 2000-04-26 | Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9910119.8 | 1999-04-30 | ||
GBGB9910119.8A GB9910119D0 (en) | 1999-04-30 | 1999-04-30 | Organic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000066724A2 WO2000066724A2 (en) | 2000-11-09 |
WO2000066724A3 true WO2000066724A3 (en) | 2001-02-08 |
Family
ID=10852654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/003708 WO2000066724A2 (en) | 1999-04-30 | 2000-04-26 | Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1181361A2 (en) |
AU (1) | AU4402500A (en) |
GB (1) | GB9910119D0 (en) |
WO (1) | WO2000066724A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2832154B1 (en) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE |
DE10258677A1 (en) * | 2002-12-13 | 2004-06-24 | Elez, Vera, Dr. | Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect |
FR2852606A1 (en) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | In vitro method for simultaneous inhibition of several genes, useful for treating cancer or viral infection, using a ligand that binds to a common site in the genes and induces cutting by topoisomerase |
CN110623956A (en) | 2014-01-28 | 2019-12-31 | 巴克老龄化研究所 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008350A1 (en) * | 1993-09-20 | 1995-03-30 | Reed John C | REGULATION OF bcl-2 GENE EXPRESSION |
WO1995031470A2 (en) * | 1994-05-13 | 1995-11-23 | Merck Frosst Canada Inc. | Antisense inhibitors of gene expression |
US5470974A (en) * | 1985-03-15 | 1995-11-28 | Neu-Gene Development Group | Uncharged polynucleotide-binding polymers |
WO1998018812A1 (en) * | 1996-10-25 | 1998-05-07 | Hisamitsu Pharmaceutical Co., Inc. | Oligomers which inhibit the expression of interleukin genes |
WO2000001393A2 (en) * | 1998-07-02 | 2000-01-13 | The Trustees Of Columbia University In The City Of New York | OLIGONUCLEOTIDE INHIBITORS OF bcl-xL |
WO2000020432A1 (en) * | 1998-10-07 | 2000-04-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
-
1999
- 1999-04-30 GB GBGB9910119.8A patent/GB9910119D0/en not_active Ceased
-
2000
- 2000-04-26 EP EP00925239A patent/EP1181361A2/en not_active Withdrawn
- 2000-04-26 AU AU44025/00A patent/AU4402500A/en not_active Abandoned
- 2000-04-26 WO PCT/EP2000/003708 patent/WO2000066724A2/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5470974A (en) * | 1985-03-15 | 1995-11-28 | Neu-Gene Development Group | Uncharged polynucleotide-binding polymers |
WO1995008350A1 (en) * | 1993-09-20 | 1995-03-30 | Reed John C | REGULATION OF bcl-2 GENE EXPRESSION |
WO1995031470A2 (en) * | 1994-05-13 | 1995-11-23 | Merck Frosst Canada Inc. | Antisense inhibitors of gene expression |
WO1998018812A1 (en) * | 1996-10-25 | 1998-05-07 | Hisamitsu Pharmaceutical Co., Inc. | Oligomers which inhibit the expression of interleukin genes |
WO2000001393A2 (en) * | 1998-07-02 | 2000-01-13 | The Trustees Of Columbia University In The City Of New York | OLIGONUCLEOTIDE INHIBITORS OF bcl-xL |
WO2000020432A1 (en) * | 1998-10-07 | 2000-04-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
Non-Patent Citations (7)
Title |
---|
GAUTSCHI OLIVER ET AL: "Potent anti-tumor activity of a bcl-2/bcl-xL bispecific antisense oligonucleotide against solid tumors of diverse histological origin.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 642, XP000926075, ISSN: 0197-016X * |
LEUDKE G H ET AL: "Antisense oligodeoxynucleotides designed to downregulates the expression of bcl-xL and of bcl-2 and bcl-xL simultaneously, restore the apoptotic response of lung cancer cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 417, XP000960954, ISSN: 0197-016X * |
LUEDTKE G H ET AL: "Antisense oligonucleotides targeting sequences shared by the Bcl-2 and Bcl-xL efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. 38, 1997, pages 170, XP002080870 * |
OBIKA S ET AL: "Properties of Novel Oligonucleotide Analogues Containing an Acyclic Nucleoside and a Carbamate Linkage", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 12, 18 June 1996 (1996-06-18), pages 1357 - 1360, XP004134840, ISSN: 0960-894X * |
ZANGEMEISTER-WITTKE U ET AL: "Bcl-2 antisense oligodeoxynucleotide 2009 synergizes with chemotherapy on lung cancer cell lines and has antitumor activity against lung cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 39, March 1998 (1998-03-01), 89th Annual Meeting of the American Association for Cancer Research;New Orleans, Louisiana, USA; March 28-April 1, 1998, March, 1998, pages 417, XP002153619, ISSN: 0197-016X * |
ZANGEMEISTER-WITTKE U ET AL: "Novel approaches to the treatment of small-cell lung cancer.", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 55, no. 12, September 1999 (1999-09-01), pages 1585 - 1598, XP000960960, ISSN: 1420-682X * |
ZANGEMEISTER-WITTKE U ET AL: "Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.", BRITISH JOURNAL OF CANCER, vol. 78, no. 8, October 1998 (1998-10-01), pages 1035 - 1042, XP000965123, ISSN: 0007-0920 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000066724A2 (en) | 2000-11-09 |
EP1181361A2 (en) | 2002-02-27 |
GB9910119D0 (en) | 1999-06-30 |
AU4402500A (en) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
EP2332955A3 (en) | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression | |
WO2002041837A3 (en) | Treatment of mucositis | |
AU2989900A (en) | Microwave systems for medical hyperthermia, thermotherapy and diagnosis | |
HK1044545A1 (en) | Human beta-secretase enzyme, inhibitors and their compositions and uses | |
HUP0401192A3 (en) | Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds | |
EP2221376A3 (en) | Antisense modulation of superoxide dismutase 1, soluble expression | |
AU2208401A (en) | Inhibitors of complement activation, their preparation and use | |
CA2368574A1 (en) | Compositions for preventing and treating type i allergy | |
WO2002026191A3 (en) | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue | |
AUPQ879500A0 (en) | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease | |
MXPA02012249A (en) | Peptides, compositions and methods for the treatment of burkholderia cepacia. | |
AU2002226030A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
MXPA03009984A (en) | Preparation for the removal of abnormal keratin material. | |
DE60202590D1 (en) | 2H-1-BENZOPYRANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
AU2001282730A1 (en) | Seal-oil-based pharmaceutical, cosmetic, dermo-cosmetic, hygiene, alimentary andpara-alimentary (food-supplements) products; their methods of preparation; thei r uses as preventive and/or as therapeutic agents | |
WO2000066724A3 (en) | Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna | |
AU5539798A (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | |
AU6866500A (en) | Chromone derivatives, process for the preparation of the same and uses thereof | |
HUP0203212A3 (en) | Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions | |
HUP0201810A3 (en) | Sootepenseone and its derivatives, their preparation and use as medicament | |
HUP0200343A3 (en) | Phenylalaninol derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
AU2001240820A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular dementia | |
AU2001237518A1 (en) | Polyfluoroalkylimidazole derivatives, their preparation and therapeutic application | |
AU2001274000A1 (en) | Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AU BA BG BR CA CN CZ EE GE HR HU ID IL IN JP KR LT LV MK MX NO NZ PL RO SG SI SK TR UA US VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000925239 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000925239 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018437 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000925239 Country of ref document: EP |